PharmaBusinessReview
Techstars '23London, GB · Founded 2021 · 22 employees on LinkedIn · 2 known investors
PBR Life Sciences provides AI-powered analytics and market intelligence for healthcare organizations operating in emerging markets, particularly in Sub-Saharan Africa. The company delivers data-as-a-service insights to pharmaceutical companies, NGOs, and life sciences organizations.
Also known as PBR Insight · PBR Life Sciences
Investors · 2
Company profile
researched Aug 2026PharmaBusinessReview, operating as PBR Life Sciences, provides market data, analytics and advisory services for the pharmaceutical, healthcare and global health sectors in emerging markets, with a stated focus on African pharmaceuticals. Its offering combines proprietary data platforms with local market expertise to answer commercial questions such as which products to launch, in which markets, and how to compete. The company frames its data around indicators including a Nigerian pharmaceutical market projected at $1.01 billion by 2028, a Nigerian population projected to exceed 377 million by 2050, and roughly 70% import reliance in that market.
The business is organised into several lines: market data and intelligence platforms (AI-powered digital products delivering multi-variate, multi-channel real-world market insights); analytics and advisory, including customised data solutions, forecasting models and strategic recommendations for life sciences companies; global health analytics and advisory aimed at global health organisations, policymakers and private-sector players; research consultancy covering qualitative and quantitative studies; and health systems intelligence for governments and NGOs. Named products include VERSUS (retail pharmacy analytics for Nigeria), VERSUS Ghana (retail pharmacy analytics for Ghana), Invisio (hospital analytics), Research Data Lab (an analytics engine positioned for global health innovation originating from Africa) and Easystock, a financing product for retail pharmacy stock. The company also publishes market intelligence reports and white papers, and references coverage spanning 78 therapy areas and a $45.3 billion global antibiotics market.
Business model
PBR Life Sciences sells subscription access to its data and analytics platforms alongside project-based consulting, research and advisory engagements, and offers embedded finance and business tools such as Easystock inventory financing for retail pharmacies. Data supply is reciprocal: pharmacies join a data partner programme, contributing anonymised transaction data in exchange for insights, which feeds the platforms sold to industry clients.
Revenue is derived from platform subscriptions (VERSUS, VERSUS Ghana, Invisio, Research Data Lab), paid market intelligence reports and white papers, customised analytics and advisory mandates, and financial products for healthcare providers.
Traction
The website reports coverage of more than 8,269 brands and 10,958 SKUs, over 1,000 partnerships, and more than 1,000 pharmacies in Nigeria, Ghana and Kenya participating in its data partner programme. It also cites a $1M figure under "Company Growth."
Latest developments
PharmaBusinessReview was named among the 12 companies in the ARM Labs Lagos Techstars Accelerator cohort disclosed in Techstars' February 2024 update. Its current product line-up spans retail pharmacy analytics in Nigeria and Ghana, hospital analytics, a research analytics engine and pharmacy stock financing.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company positions itself as a provider of pharmaceutical market intelligence for African and other emerging markets, describing its Research Data Lab analytics engine as a first-of-its-kind engine for global health innovation from Africa.
Stated differentiators are proprietary, primary-collected retail pharmacy and hospital data from African markets, combined with local expertise, AI-based analytics and adjacent tools such as pharmacy stock financing that deepen data-partner relationships.
Technology
The company describes AI-powered digital platforms that aggregate multi-variate, multi-channel real-world market data from retail pharmacy and hospital channels, plus an analytics engine (Research Data Lab) and forecasting models used to generate market and therapy-area insights.
Go-to-market
Distribution combines direct enterprise sales and advisory relationships with life sciences and global health clients, a data partner programme recruiting pharmacies across Nigeria, Ghana and Kenya, and published reports and white papers. The company participated in the ARM Labs Lagos Techstars Accelerator cohort announced in February 2024, a mentorship-driven programme that invests $120,000 per company.
Pharmaceutical and healthcare companies operating in or entering emerging markets, global health organisations, policymakers, governments and NGOs, and retail pharmacies and hospitals that act as both data partners and users of financing tools.
Geography
Operations centre on Sub-Saharan Africa, with named coverage and products for Nigeria, Ghana and Kenya, and advisory positioned for emerging and global markets.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsTechstars' February 2024 update listed PharmaBusinessReview among the companies in the ARM Labs Lagos Techstars Accelerator cohort; Techstars states it invests $120,000 in companies joining its three-month accelerator programs.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureCompanies House · registry record
View on Companies House ↗- Registered name
- PHARMA BUSINESS REVIEW LIMITED
- Company number
- 12849897
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 1 Sept 2020
- Registered office
- Kemp House 152-160 City Road, London, EC1V 2NX
- Nature of business (SIC)
- 70229 — Management consultancy activities other than financial management
- Accounts
- last made up to 30 Sept 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 12 Oct 2025 · next due 26 Oct 2026
Current officers · 3
- Ayodeji Sunday Alaran — director, appointed 1 Sept 2020
- Kenechukwu Chisomeje Diobi — director, appointed 18 Oct 2023
- Teslim Sileola Kuteyi — director, appointed 26 Oct 2023
Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.
▸Research sources · 5
primary sources listed
- PharmaBusinessReviewpbrinsight.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does PharmaBusinessReview do?
- PBR Life Sciences supplies AI-driven pharmaceutical market data, analytics and advisory for African and emerging markets.
- Who are PharmaBusinessReview's investors?
- PharmaBusinessReview's investors include Microtraction, Techstars.
- Where is PharmaBusinessReview headquartered?
- PharmaBusinessReview is headquartered in London, GB.